IZIDORE LOSSOS
Medical Practice at 35 St, Hollywood, FL

2011020, Aug 18, 2011

Dec 1, 2010

12/957600

Izidore Lossos - Miami FL, US
Alvero Alencar - Carlsbad NM, US
Raquel Malumbres - Huarte, ES
Robert Tibshirani - Stanford CA, US

UNIVERSITY OF MIAMI - Miami FL

C12Q 1/68

435 612, 435 61, 435 617, 435 613

Assays, methods and kits for predicting survival outcome in a subject having diffuse large B-cell lymphoma (DLBCL) and for measuring a subject's response to DLBCL therapy involve specific miRNAs that are prognostic biomarkers for prediction of outcome of DLBCL patients. Expression of miRNAs miR-18a, miR-181a and miR-222 is associated with response to therapy and outcome of patients with DLBCL. Measurement of these miRs can be used to identify patients' outcomes in the clinic and allow tailoring of patient-specific therapy.

7622253, Nov 24, 2009

Oct 3, 2006

11/542552

Ronald Levy - Stanford CA, US
Mark A. Wechser - Moraga CA, US
Izidore S. Lossos - Miami FL, US
Robert J. Tibshirani - Palo Alto CA, US
Ash A. Alizadeh - San Mateo CA, US
David Botstein - Princeton NJ, US

G01N 33/50, C12Q 1/68, G01N 33/574

435 6, 435 4, 435 721, 435 723, 702 20

Methods and kits for classifying patients having diffuse large B-cell lymphoma (DLBCL) based upon expression of a plurality of genes are disclosed. Real-time quantitative RT-PCR can be used to measure expression values. Correlating expression values of the plurality of genes in a tumor sample from the patient to reference expression values obtained from DLBCL patients can stratify patients in the classification groups. The methods and kits can be used to predict overall patient survival.

2012013, May 31, 2012

Oct 5, 2011

13/253491

Arash Ash Alizadeh - San Mateo CA, US
Ronald Levy - Stanford CA, US
Andrew J. Gentles - Menlo Park CA, US
Izidore S. Lossos - Miami FL, US

A61K 39/395, A61P 35/00, A61K 31/4375, A61K 31/56, A61K 31/66, A61K 31/704

4241331, 514110, 514 34, 514283, 514179

Measurement of a single gene expressed by tumor cells (LMO2) and a single gene expressed by the immune microenvironment (TNFRSF9), which determination may be referred to herein as a two gene score (TGS), powerfully predicts overall survival in patients with NHL, particularly overall survival in the context of anthracycline-based chemotherapy or co-treatment with anthracycline-based chemotherapy and anti-CD20 immunotherapy. It is shown herein that increased levels of LMO2 and TNFRSF9 correlate with a positive patient response and improved prognosis.

2010014, Jun 10, 2010

Nov 24, 2009

12/625523

Ronald Levy - Stanford CA, US
Mark A. Wechser - Moraga CA, US
Izidore S. Lossos - Miami FL, US
Robert J. Tibshirani - Palo Alto CA, US
Ash A. Alizadeh - San Mateo CA, US
David Botstein - Princeton NJ, US

LIFE TECHNOLOGIES CORPORATION - Carlsbad CA

C12Q 1/68

435 6

Methods and kits for classifying patients having diffuse large B-cell lymphoma (DLBCL) based upon expression of a plurality of genes are disclosed. Real-time quantitative RT-PCR can be used to measure expression values. Correlating expression values of the plurality of genes in a tumor sample from the patient to reference expression values obtained from DLBCL patients can stratify patients in the classification groups. The methods and kits can be used to predict overall patient survival.

2005007, Apr 14, 2005

Mar 3, 2004

10/792374

Ronald Levy - Stanford CA, US
Mark Wechser - Moraga CA, US
Izidore Lossos - Miami FL, US
Robert Tibshirani - Palo Alto CA, US
Ash Alizadeh - San Mateo CA, US
David Botstein - Princeton NJ, US

C12Q001/68, G01N033/574

435006000, 435007230

Methods and kits for classifying patients having diffuse large B-cell lymphoma (DLBCL) based upon expression of a plurality of genes are disclosed. Real-time quantitative RT-PCR can be used to measure expression values. Correlating expression values of the plurality of genes in a tumor sample from the patient to reference expression values obtained from DLBCL patients can stratify patients in the classification groups. The methods and kits can be used to predict overall patient survival.